ClinicalTrialsFinder
RecruitingPhase 2NCT05761366

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment

400 participants

Start Date

Oct 13, 2022

Study Type

INTERVENTIONAL

Conditions

Malignancy

Summary

In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patients with suspected or clearly diagnosed PSMA positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.
  • Age is 18 or older; No gender limitation.
  • Signed the informed consent.
  • Willing and able to cooperate with all projects in this study.

Exclusion Criteria4

  • Patients with serious neurological diseases,or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc
  • Claustrophobia.
  • Pregnant or lactation women.
  • Received experimental drug or device within 1 month.

Interventions

DRUGAl18F-PSMA-BCH PET/CT

Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.

Locations(1)

National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Chaoyang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05761366

Related Trials

Target-specific immunoPET Imaging of Digestive System Carcinoma

NCT067158391 location

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

NCT0577010227 locations

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

NCT0577054427 locations

The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease

NCT041224691 location